MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
NCT ID: NCT00266344
Last Updated: 2015-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
520 participants
INTERVENTIONAL
2005-11-30
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
NCT00266357
Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)
NCT00094627
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)
NCT00094666
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)
NCT00095069
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)
NCT00102154
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK0928, gaboxadol / Duration of Treatment 3 Weeks
Placebo / Duration of Treatment 3 Weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Merck & Co., Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK0928-040
Identifier Type: -
Identifier Source: secondary_id
2005_106
Identifier Type: -
Identifier Source: secondary_id
0928-040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.